Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 12 (Search time: 0.004 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2014
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, T.
;
Saglio, G.
;
Kantarjian, H.
;
Guilhot, F.
;
Niederwieser, D.
;
Rosti, G.
;
Nakaseko, C.
;
De Souza, C.
;
Kalaycio, M.
;
Meier, S.
;
Fan, X.
;
Menssen, H.
;
Larson, R.
;
Hochhaus, A.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian, H.
;
Hochhaus, A.
;
Saglio, G.
;
de Souza, C.
;
Flinn, I.
;
Stenke, L.
;
Goh, Y.
;
Rosti, G.
;
Nakamae, H.
;
Gallagher, N.
;
Hoenekopp, A.
;
Blakesley, R.
;
Larson, R.
;
Hughes, T.
2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
O'Brien, S.
;
Guilhot, F.
;
Larson, R.
;
Gathmann, I.
;
Baccarani, M.
;
Cervantes, F.
;
Cornelissen, J.
;
Fischer, T.
;
Hochhaus, A.
;
Hughes, T.
;
Lechner, K.
;
Nielsen, J.
;
Rousselot, P.
;
Reiffers, J.
;
Saglio, G.
;
Shepherd, J.
;
Simonsson, B.
;
Gratwohl, A.
;
Goldman, J.
;
Kantarjian, H.
;
et al.
2010
Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia
Saglio, G.
;
Kim, D.
;
Issaragrisil, S.
;
le Coutre, P.
;
Etienne, G.
;
Lobo, C.
;
Pasquini, R.
;
Clark, R.
;
Hochhaus, A.
;
Hughes, T.
;
Gallagher, N.
;
Hoenekopp, A.
;
Haque, A.
;
Dong, M.
;
Larson, R.
;
Kantarjian, H.
2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Hughes, T.
;
Hochhaus, A.
;
Branford, S.
;
Muller, M.
;
Kaeda, J.
;
Foroni, L.
;
Druker, B.
;
Guilhot, F.
;
Larson, R.
;
O'Brien, S.
;
Rudoltz, M.
;
Mone, M.
;
Wehrle, E.
;
Modur, V.
;
Goldman, J.
;
Radich, J.
2009
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Baccarani, M.
;
Cortes, J.
;
Pane, F.
;
Niederwieser, D.
;
Saglio, G.
;
Apperley, J.
;
Cervantes, F.
;
Deininger, M.
;
Gratwohl, A.
;
Guilhot, F.
;
Hochhaus, A.
;
Horowitz, M.
;
Hughes, T.
;
Kantarjian, H.
;
Larson, R.
;
Radich, J.
;
Simonsson, B.
;
Silver, R.
;
Goldman, J.
;
Hehlmann, R.
Discover
Author
12
Hochhaus, A.
9
Kantarjian, H.
9
Saglio, G.
6
Guilhot, F.
6
Kim, D.
6
Rosti, G.
5
Baccarani, M.
5
Cortes, J.
4
Apperley, J.
4
Cervantes, F.
.
next >
Subject
12
Benzamides
12
Pyrimidines
11
Antineoplastic Agents
11
Humans
11
Imatinib Mesylate
7
Leukemia, Myelogenous, Chronic, B...
7
Treatment Outcome
6
Adult
6
Aged
6
Fusion Proteins, bcr-abl
.
next >
Date issued
8
2010 - 2014
4
2003 - 2009